Kestra Advisory Services’s Protagonist Therapeutics PTGX Stock Holding History

Kestra Advisory Services’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$742K	Buy	5,267 +206	+4%	+$29.4K	﹤0.01%	2172
2026 Q2	$620K	Buy	5,061 +7	+0.1%	+$731	﹤0.01%	2175
2026 Q1	$533K	Sell	5,054 -88	-2%	-$7.79K	﹤0.01%	2171
2025 Q4	$449K	Sell	5,142 -81	-2%	-$6.63K	﹤0.01%	2238
2025 Q3	$347K	Sell	5,223 -540	-9%	-$30.7K	﹤0.01%	2325
2025 Q2	$319K	Buy	5,763 +582	+11%	+$27.9K	﹤0.01%	2298
2025 Q1	$251K	Sell	5,181 -466	-8%	-$19.5K	﹤0.01%	2309
2024 Q4	$218K	Buy	5,647 +464	+9%	+$20.2K	﹤0.01%	2434
2024 Q3	$233K	Buy	+5,183	New	+$209K	﹤0.01%	2263
2022 Q1	–	Sell	-7,833	Closed	-$268K	–	2099
2021 Q4	$268K	Buy	+7,833	New	+$248K	﹤0.01%	1672
2021 Q3	–	Sell	-13,939	Closed	-$626K	–	2164
2021 Q2	$626K	Buy	13,939 +310	+2%	+$10.2K	0.01%	1163
2021 Q1	$353K	Buy	+13,629	New	+$345K	﹤0.01%	1365

Other funds holding PTGX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Kestra Advisory Services's PTGX Position: Q3 2026 in Review

Kestra Advisory Services increased its Protagonist Therapeutics (PTGX) stake by 4.1% in Q3 2026, buying an estimated $29.4K and bringing the position to 5,267 shares worth $742K. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

Kestra Advisory Services first reported a position in PTGX in Q1 2021 and has held it in 12 quarters since. 294 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

Kestra Advisory Services held 5,267 shares of Protagonist Therapeutics worth $742K as of Q3 2026.
Kestra Advisory Services bought 206 Protagonist Therapeutics shares in Q3 2026, an estimated $29.4K.
Protagonist Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #2172 holding.
Kestra Advisory Services first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 12 quarters since.
294 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.